Comparison of the effectiveness of olanzapine, metoclopramide and domperidone for controlling chemotherapy related nausea and vomiting

Phase 2

• Conditions: Health Condition 1: C00-D49- Neoplasms

• Registration Number: CTRI/2018/11/016359
• Lead Sponsor: Jawaharlal Institute Of Postgraduate Medical Education and Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Histologically or cytologically confirmed malignant disease

2.Chemotherapy naïve patients

3.Scheduled to receive intravenous either single or multiday highly emetogenetic chemotherapy regimens or moderately emetogenic chemotherapy regimens

Exclusion Criteria

1.Patients with nausea in 24 h prior to beginning of chemotherapy

2.serum creatinine of >2.0 mg/dl, serum bilirubin of >2.0 mg/dl, SGOT or SGPT values of >3 times the upper limits of normal

3.Pregnant patients

4.Patients on chemotherapy for leukemia.

5.Esophageal and stomach malignancies are excluded from the study.

6.Patients on continuous, intermittent or concomitant oral chemotherapy

7.Patients on continuous, intermittent or concomitant oral chemotherapy or on opioid (morphine) treatment for pain control.

8.Patients with known hypersensitivity to olanzapine, metoclopramide or domperidone,

9.Patients with cardiac arrhythmia, history of congestive heart failure, or acute myocardial infarction within the previous 6 months.

10.Patients with known history of CNS disease (e.g., brain metastases, seizure disorder), or treatment with any antipsychotic agents such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for 30 days prior to or during protocol therapy.

11.Patients with concurrent abdominal radiotherapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified